Stock AMPH AMPHASTAR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
42.02 USD +2.21% Intraday chart for Amphastar Pharmaceuticals, Inc. +4.61% -32.06%
Mar. 13 Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Mar. 08 Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 905.4 955.3 1,114 1,354 2,963 2,053 - -
Enterprise Value (EV) 1 905.4 955.3 1,114 1,354 2,963 2,491 2,279 2,046
P/E ratio 19.7 x 670 x 18.6 x 16.1 x 23.8 x 11.8 x 10.2 x 8.78 x
Yield - - - - - - - -
Capitalization / Revenue 2.81 x 2.73 x 2.55 x 2.71 x 4.6 x 2.65 x 2.4 x 2.15 x
EV / Revenue 2.81 x 2.73 x 2.55 x 2.71 x 4.6 x 3.22 x 2.66 x 2.15 x
EV / EBITDA 25.3 x 16.8 x 11.2 x 9.21 x 10.4 x 8.22 x 6.7 x 5.21 x
EV / FCF 4,374 x - - 20.8 x - 15.1 x 10.5 x 8.02 x
FCF Yield 0.02% - - 4.81% - 6.62% 9.56% 12.5%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 46,938 47,504 47,849 48,331 47,907 48,866 - -
Reference price 2 19.29 20.11 23.29 28.02 61.85 42.02 42.02 42.02
Announcement Date 3/12/20 3/15/21 3/10/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 322.4 349.8 437.8 499 644.4 774.7 856 953.5
EBITDA 1 35.73 56.75 99.1 147.1 283.9 302.9 340 392.9
EBIT 1 18.66 36.26 76.9 121.8 245.8 267 299.2 350.2
Operating Margin 5.79% 10.36% 17.57% 24.42% 38.15% 34.46% 34.95% 36.72%
Earnings before Tax (EBT) - - - - - - - -
Net income 1 - 1.403 62.12 91.39 137.5 189.4 219.3 254.2
Net margin - 0.4% 14.19% 18.31% 21.34% 24.45% 25.63% 26.66%
EPS 2 0.9800 0.0300 1.250 1.740 2.600 3.572 4.132 4.785
Free Cash Flow 1 0.207 - - 65.15 - 165 218 255
FCF margin 0.06% - - 13.06% - 21.3% 25.47% 26.74%
FCF Conversion (EBITDA) 0.58% - - 44.29% - 54.47% 64.12% 64.9%
FCF Conversion (Net income) - - - 71.29% - 87.11% 99.38% 100.32%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/12/20 3/15/21 3/10/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 112.2 120.9 120.4 123.5 120.1 135 140 145.7 180.6 178.1 175.5 180.3 205.8 211.6 212.8
EBITDA 1 34.44 31.15 - - - 49 - - - 80.5 69.11 73.57 90.17 86.05 -
EBIT 1 15.5 25.75 21.64 24.82 27.92 42.47 41 48.01 89.16 67.67 57.47 58.99 73.51 75.37 70.7
Operating Margin 13.82% 21.3% 17.98% 20.1% 23.24% 31.45% 29.28% 32.95% 49.38% 38% 32.75% 32.72% 35.71% 35.63% 33.22%
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income 1 29.55 19.76 - - - 33.91 - - - - 42.06 42.75 50.64 49.77 -
Net margin 26.34% 16.35% - - - 25.12% - - - - 23.97% 23.71% 24.6% 23.52% -
EPS 2 - - 0.4700 0.3300 0.3000 0.6600 - 0.4900 - - 0.7894 0.7848 0.9924 1.000 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/8/21 3/10/22 5/9/22 8/8/22 11/7/22 2/28/23 5/9/23 8/8/23 11/8/23 2/28/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 438 226 -
Net Cash position 1 - - - - - - - 7.31
Leverage (Debt/EBITDA) - - - - - 1.445 x 0.665 x -
Free Cash Flow 1 0.21 - - 65.1 - 165 218 255
ROE (net income / shareholders' equity) - - - - 30.1% 25.4% 27% 24.5%
ROA (Net income/ Total Assets) - - - - - 12.4% 12.8% 13.2%
Assets 1 - - - - - 1,528 1,710 1,926
Book Value Per Share - - - - - - - -
Cash Flow per Share 2 - - - - 3.460 0.5800 4.330 -
Capex 1 41.6 33.9 27.5 24 38.2 32.5 32.5 32.5
Capex / Sales 12.89% 9.68% 6.27% 4.82% 5.92% 4.2% 3.8% 3.41%
Announcement Date 3/12/20 3/15/21 3/10/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Amphastar Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
42.02 USD
Average target price
62.6 USD
Spread / Average Target
+48.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AMPHASTAR PHARMACEUTICALS, INC. Stock Amphastar Pharmaceuticals, Inc.
-32.06% 2.01B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AMPH Stock
  4. Financials Amphastar Pharmaceuticals, Inc.